Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025, for GlycoMimetics, Inc. (trading symbol: GLYC), a biotechnology company currently in the process of a strategic merger. The company previously developed glycomimetics for cancer treatment but halted development of its lead candidate, uproleselan, following Phase 3 trial results in 2024. On October 28, 2024, the company entered into a merger agreement with Crescent Biopharma, Inc., under which the combined entity will operate as Crescent Biopharma, Inc. The merger is expected to close in the second quarter of 2025, contingent on shareholder approval and other conditions.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,343,736) | $(10,736,667) |
| Net Loss Per Share (Basic & Diluted) | $(0.04) | $(0.17) |
| Operating Cash Flow | $(5,105,992) | $(10,508,829) |
| Cash and Cash Equivalents (End of Period) | $5,614,186 | $31,281,460 |
| Total Assets | $5,992,180 | $11,091,454 |
| Total Liabilities | $2,616,926 | $5,777,892 |
| Stockholders' Equity | $3,375,254 | $28,910,712 |
Note: The filing text does not provide specific margin percentages as the company has no revenue.
Material Changes Versus Prior Period
- Expense Reduction: Total costs and expenses decreased by 78% to $2.4 million from $11.1 million in the prior year quarter. This is primarily due to the winding down of operations and an 80% workforce reduction initiated in July 2024.
- Research and Development (R&D): R&D expenses plummeted to $14,776 from $6.0 million, reflecting the cessation of clinical trials and development activities.
- General and Administrative (G&A): G&A expenses decreased by 53% to $2.4 million, driven by lower personnel costs and professional fees.
- Liquidity: Cash and cash equivalents declined by approximately $5.1 million during the quarter, reducing the balance from $10.7 million to $5.6 million.
- Accrued Liabilities: Accrued expenses dropped significantly from $5.4 million to $2.5 million, largely due to the payment of severance costs accrued in the prior year.
Outlook, Risks, and Management Commentary
- Merger and Private Placement: The company is awaiting the closing of the merger with Crescent Biopharma, Inc., expected in Q2 2025. Concurrently, a Private Placement (PIPE) of approximately $200 million is planned to close immediately following the merger.
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date without the closing of the merger and private placement. If the transaction does not close by Q3 2025, the company may seek other strategic alternatives or liquidate.
- Operational Status: The company has no ongoing clinical trials and has suspended R&D activities. Operations are currently limited to maintaining the business for the merger.
- Severance Obligations: As of March 31, 2025, an accrued severance liability of $1.7 million remains payable within the next twelve months.
- License Termination: The collaboration agreement with Apollomics was terminated effective May 21, 2025.
Key Facts for Investor Verification
- Merger Closing Conditions: Verify the status of shareholder approvals and other closing conditions required for the merger with Crescent Biopharma, Inc.
- Private Placement Execution: Confirm the commitment and closing of the $200 million PIPE investment, which is critical for the post-merger capitalization.
- Cash Runway: Monitor the burn rate against the current $5.6 million cash balance to ensure sufficiency until the merger closes.
- Severance Payments: Track the payment of the remaining $1.7 million in accrued severance liabilities.
- Regulatory Status: Confirm that no new regulatory hurdles have emerged regarding the merger or the assets being transferred.